SCYNEXIS (SCYX)
NASDAQ:SCYX
Top Page
SCYNEXIS
(NASDAQ:SCYX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.90
▲(36.06% Upside)
Action:ReiteratedDate:03/05/26
The score is held back primarily by inconsistent and currently loss-making financial performance (negative margins and negative free cash flow). The strengthened, low-leverage balance sheet is the main offsetting positive, while technical indicators are neutral-to-slightly positive and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Balance sheet strength
Material deleveraging and a sizable equity base provide durable financial flexibility. Low debt reduces near-term refinancing risk and supports continued R&D, regulatory work, and commercialization spend over the next several months without immediate reliance on dilutive financing.
Negative Factors
Highly volatile revenue
Extreme swings in revenue undermine predictability for forecasting, capacity planning, and sustainable margin improvement. Such volatility suggests earnings are sensitive to episodic events or partner actions, raising execution and commercial risk over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Material deleveraging and a sizable equity base provide durable financial flexibility. Low debt reduces near-term refinancing risk and supports continued R&D, regulatory work, and commercialization spend over the next several months without immediate reliance on dilutive financing.
Read all positive factors
SCYNEXIS (SCYX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.41M
Dividend YieldN/A
Average Volume (3M)612.75K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue Growth-65.77%
EPS Growth38.61%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.25
Shares Outstanding44,663,834
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda1.12
Forecast
1Y Price Target
$3.50Price Target Upside430.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$1.15M
SCYNEXIS Business Overview & Revenue Model
Company Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its le...
How the Company Makes Money
SCYNEXIS generates revenue primarily from (1) product sales of its approved antifungal, Brexafemme (ibrexafungerp), through commercialization in markets where it or its commercial partners sell the product, and (2) collaboration-related income suc...
SCYNEXIS Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.60M | 3.75M | 140.14M | 5.09M | 13.16M |
| Gross Profit | 20.60M | 3.75M | 124.52M | 4.46M | 12.85M |
| EBITDA | -16.07M | -18.58M | 70.89M | -59.91M | -32.91M |
| Net Income | -8.61M | -21.29M | 67.04M | -62.81M | -32.87M |
Balance Sheet | |||||
| Total Assets | 59.03M | 90.64M | 128.41M | 87.81M | 119.84M |
| Cash, Cash Equivalents and Short-Term Investments | 21.26M | 59.30M | 74.36M | 73.50M | 104.48M |
| Total Debt | 2.17M | 16.27M | 15.08M | 48.60M | 43.63M |
| Total Liabilities | 9.65M | 35.57M | 55.45M | 84.58M | 78.58M |
| Stockholders Equity | 49.38M | 55.08M | 72.96M | 3.23M | 41.26M |
Cash Flow | |||||
| Free Cash Flow | -5.28M | -24.01M | 60.16M | -79.89M | -55.73M |
| Operating Cash Flow | -5.28M | -24.01M | 60.16M | -79.88M | -54.56M |
| Investing Cash Flow | 24.31M | 6.15M | -34.88M | -27.39M | -1.17M |
| Financing Cash Flow | -14.17M | -139.00K | -36.72M | 48.60M | 67.12M |
SCYNEXIS Technical Analysis
Neutral
0.66
Price Trends
0.79
Positive
0.71
Positive
0.77
Positive
Market Momentum
0.03
Positive
49.98
Neutral
28.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Neutral. The current price of 0.66 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.79, and below the 200-day MA of 0.77, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 49.98 is Neutral, neither overbought nor oversold. The STOCH value of 28.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SCYX.
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SCYNEXIS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $37.12M | >-0.01 | -16.77% | ― | -23.60% | -179.33% | |
52 Neutral | $25.70M | 20.56 | 0.27% | ― | 75.19% | ― | |
52 Neutral | $48.46M | -10.54 | -10.54% | ― | 12.21% | 69.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $37.41M | -3.67 | -19.05% | ― | -65.77% | 38.61% | |
45 Neutral | $28.55M | -0.62 | -107.16% | ― | -15.61% | -68.96% | |
40 Underperform | $2.64M | -0.89 | -93.87% | ― | -0.74% | 81.49% |
* Healthcare Sector Average
SCYX
SCYNEXIS
0.84
-0.17
-17.13%
RMTI
Rockwell Med
0.94
-0.26
-21.50%
TXMD
TherapeuticsMD
2.22
1.17
111.43%
AYTU
Aytu BioScience
2.66
1.42
114.52%
CPIX
Cumberland Pharmaceuticals
3.24
-0.89
-21.55%
IMCC
IM Cannabis Corp
0.50
-1.25
-71.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.